Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedSep 23, 2015Tri-Mix ST3/PGE 2/LIDO 2 0.06/0.2/0.02 InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1795-2015Class IITerminatedSep 23, 2015Tri-Mix ST2/LIDO2/PGE2 0.2/0.1/0.04Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1794-2015Class IITerminatedSep 23, 2015Tri-Mix ST2Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1793-2015Class IITerminatedSep 23, 2015Tri-Mix ST1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1792-2015Class IITerminatedSep 23, 2015Tri-Mix MEDIUMLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1791-2015Class IITerminatedSep 23, 2015Tri-Mix MEDIUMLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1790-2015Class IITerminatedSep 23, 2015Tri-Mix AT-6Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1789-2015Class IITerminatedSep 23, 2015Tri-Mix AT-1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1788-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1787-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1786-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1785-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1784-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1783-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1782-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1781-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1780-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1779-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1778-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1777-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1776-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1775-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1774-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1773-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1772-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1771-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1770-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1769-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1768-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1767-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1766-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1765-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1764-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1763-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1762-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1761-2015Class IITerminatedSep 23, 2015Testosterone Tri-Blend 200 mg/mlLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1760-2015Class IITerminatedSep 23, 2015Testosterone Cypionate 40 mg/ml InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1759-2015Class IITerminatedSep 23, 2015Testosterone Cypionate 250 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1758-2015Class IITerminatedSep 23, 2015Testosterone Cypionate 40 mg/mlLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1757-2015Class IITerminatedSep 23, 2015Testosterone Cypionate 220 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1756-2015